Physician profile
Sheila Wolfrum
NPI 1194355982
$4,178.99
in general payments reported to CMS, 2019-2025
19 companies · $1,472 in 2025
The $1,472 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $207 · 2023: $1,271 · 2024: $1,228 · 2025: $1,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,861 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,860.54 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $589.29 | 2023-2025 | Uzedy, Austedo Xr, Austedo |
| Lundbeck LLC | $515.36 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $476.33 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $472.18 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $372.66 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $305.97 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $231.76 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $221.53 | 2023-2025 | Dyanavel Xr |
| Alkermes, INC. | $216.89 | 2023-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $196.87 | 2023-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $186.11 | 2023-2025 | Ingrezza |
| Corium, LLC | $113.88 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $97.48 | 2023-2024 | Jornay Pm |
| Bayer Healthcare Pharmaceuticals INC. | $63.20 | 2022 | |
| Axsome Therapeutics, INC. | $46.15 | 2023-2024 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $27.56 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $16.19 | 2023 | Quviviq |
| Indivior INC. | $15.95 | 2024 | Perseris |
| Janssen Pharmaceuticals, INC | $13.63 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Wolfrum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.